overall survival
UNASSIGNED: e21029 Background: The global, randomized, Phase III ToGA study showed that trastuzumab (H) plus capecitabine or 5-fluorouracil and cisplatin (XP/FP) significantly improves overall survival (OS) vs XP/FP alone (median: 13.8 vs 11.1 mo, hazard ratio [HR] 0.74, P=0.0046) in patients with HER2-positive advanced gastric or gastroesophageal junction (aGC/GEJ) cancer.